...................................................................................................................... 67 - 69 APPENDICES ....................................................................................................................... I-XVIII AND BIBLIOGRAPHY

Agarwal, N. B. and Karwa, M. (2018) ‘Chapter 12 - Pharmaceutical Regulations in India', in Vohora, D. and Singh, G. (eds) Pharmaceutical Medicine and Translational Clinical Research. Boston: Academic Press, pp. 215-231. doi: 10.1016/B978-0-12 802103-3.00013-4.

Barksdale, D. J., Newhouse, R. and Miller, J. A. (2014) ‘The Patient-Centered Outcomes Research Institute (PCORI): Information for academic nursing', Nursing Outlook, 62(3), pp. 192-200. doi: 10.1016/j.outlook.2014.03.001.

Bemt, B. J. F. van den et al. (2019) ‘A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience', Drug Delivery. Taylor & Francis, 26(1), pp. 384-392. doi: 10.1080/10717544.2019.1587043.

CDER, C. for D. E. and R. (2020) ‘CDER Patient-Focused Drug Development', FDA. FDA. Available at: https://www.fda.gov/drugs/development-approval-process-drugs/cderpatient-focused-drug-development (Accessed: 9 April 2021).

CDER, C. for D. E. and R. (2021) ‘CDER Pilot Grant Program: Standard Core Clinical Outcome Assessments (COAs) and their Related Endpoints', FDA. FDA. Available at: https://www.fda.gov/drugs/development-approval-process-drugs/cder-pilot-grantprogram-standard-core-clinical-outcome-assessments-coas-and-their-relatedendpoints (Accessed: 10 May 2021).

CTTI (2015) ‘CTTI RECOMMENDATIONS: EFFECTIVE ENGAGEMENT WITH PATIENT GROUPS AROUND CLINICAL TRIALS'.

Dorocki, S. (2014) ‘Contemporary Trends in the Development of the Pharmaceutical Industry in the World', Studies of the Industrial Geography Commission of the Polish Geographical Society, 25, pp. 108-131. doi: 10.24917/20801653.25.6.

EFPIA (2021) EFPIA Regulatory Road to Innovation. Available at: https://www.efpia.eu/about-medicines/development-of-medicines/regulationssafety-supply/efpia-regulatory-road-to-innovation/ (Accessed: 27 January 2021).

Epstein, S. (1995) ‘The Construction of Lay Expertise: AIDS Activism and the Forging of Credibility in the Reform of Clinical Trials', Science, Technology, & Human Values, 20(4), pp. 408-437. doi: 10.1177/016224399502000402.

Feeney, M. et al. (2020) ‘Utilizing patient advocates in Parkinson's disease: A proposed framework for patient engagement and the modern metrics that can determine its success', Health Expectations, 23(4), pp. 722-730. doi: https://doi.org/10.1111/hex.13064. Getz, K. (2019) ‘Reflections on the Evolution of Patient Engagement in Drug Development', Pharmaceutical Medicine, 33(3), pp. 179-185. doi: 10.1007/s40290 019-00284-1.

Gibson, A. et al. (2019) ‘Challenges and opportunities for involving patients and the public in acute antimicrobial medicine development research: an interview study', BMJ Open, 9(4), p. e024918. doi: 10.1136/bmjopen-2018-024918.

Haerry, D. et al. (2018) ‘EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Regulatory Processes', Frontiers in Medicine. Frontiers, 5. doi: 10.3389/fmed.2018.00230.

Hansen, M. B., Nørgaard, L. S. and Hallgreen, C. E. (2019) ‘How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations', Therapeutic Innovation & Regulatory Science, p. 216847901986429. doi: 10.1177/2168479019864294.

Hoos, A. et al. (2015) ‘Partnering With Patients in the Development and Lifecycle of Medicines', Therapeutic Innovation & Regulatory Science, 49(6), pp. 929-939. doi: 10.1177/2168479015580384.

Lansdowne, L. E. (2020) Exploring the Drug Development Process, Drug Discovery from Technology Networks. Available at: https://www.technologynetworks.com/drug-discovery/articles/exploring-the-drugdevelopment-process-331894 (Accessed: 29 May 2021).

Levitan, B. et al. (2018) ‘Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project', Therapeutic Innovation & Regulatory Science. SAGE Publications Inc, 52(2), pp. 220- 229. doi: 10.1177/2168479017716715.

Lowe, M. M. et al. (2016) ‘Increasing Patient Involvement in Drug Development', Value in Health, 19(6), pp. 869-878. doi: 10.1016/j.jval.2016.04.009.

Matej Mikulic (2020) Global pharmaceutical industry - statistics & facts | Statista. Available at: https://www.statista.com/topics/1764/global-pharmaceuticalindustry/#dossierSummary (Accessed: 9 May 2021).

Ocloo, J. et al. (2021) ‘Exploring the theory, barriers and enablers for patient and public involvement across health, social care and patient safety: a systematic review of reviews', Health Research Policy and Systems, 19(1), p. 8. doi: 10.1186/s12961 020-00644-3.

Patient Group Engagement (2016) Clinical Trials Transformation Initiative. Available at: https://www.ctti-clinicaltrials.org/projects/patient-groups-clinical-trials (Accessed: 10 May 2021). Peña, O. I. G., Zavala, M. Á. L. and Ruelas, H. C. (2021) ‘Pharmaceuticals Market, Consumption Trends and Disease Incidence Are Not Driving the Pharmaceutical Research on Water and Wastewater', International Journal of Environmental Research and Public Health, 18(5), p. 2532. doi: 10.3390/ijerph18052532.

du Plessis, D. et al. (2017) ‘Patient Centricity and Pharmaceutical Companies: Is It Feasible?', Therapeutic Innovation & Regulatory Science. SAGE Publications Inc, 51(4), pp. 460-467. doi: 10.1177/2168479017696268.

PWC (2020) ‘From vision to decision Pharma 2020'.

Sacristán, J. A. et al. (2016) ‘Patient involvement in clinical research: why, when, and how', Patient preference and adherence, 10, pp. 631-640. doi: 10.2147/PPA.S104259.

Schilling, I. et al. (2019) ‘Patient involvement in clinical trials: motivation and expectations differ between patients and researchers involved in a trial on urinary tract infections', Research Involvement and Engagement, 5(1), p. 15. doi: 10.1186/s40900-019-0145-3.

Schultz-Knudsen, K. et al. (2021) ‘New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels', Therapeutic Innovation & Regulatory Science, 55(3), pp. 503-513. doi: 10.1007/s43441-020-00244-x.

Teramae, F. et al. (2020) ‘Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies', Sustainability, 12(13), p. 5358. doi: 10.3390/su12135358.

Wale, J. L. et al. (2021) ‘Patients and public are important stakeholders in health technology assessment but the level of involvement is low - a call to action', Research Involvement and Engagement, 7(1), p. 1. doi: 10.1186/s40900-020-00248 9. APPENDICES